Targeted Therapy for Metastatic Renal Cell Carcinoma

Keyphrases

• Anti-vascular Endothelial Growth Factor (anti-VEGF) 20%
• Axitinib 40%
• Best Medical Treatment 20%
• Bevacizumab 20%
• Cancer Center 20%
• Cell-to-cell 20%
• Clear Cell 20%
• Clear Cell Histology 20%
• Clear-cell Metastatic Renal Cell Carcinoma 40%
• Cytokine Therapy 20%
• Everolimus 20%
• Failure Risk 20%
• Favorable Risk 40%
• First-line Regimen 20%
• High-risk Features 60%
• Humanized 20%
• Intermediate Risk 40%
• Kinase Inhibitor 20%
• Mammalian Target of Rapamycin (mTOR) 20%
• Memorials 20%
• Metastatic Renal Cell Carcinoma (mRCC) 100%
• Monoclonal Antibody 20%
• Multi-targeted Tyrosine Kinase Inhibitors 20%
• New Drugs 20%
• NewHope 20%
• Non-clear Cell 20%
• Pazopanib 20%
• Phase II Clinical Trial 20%
• Phase III Clinical Trial 40%
• Poor Risk 20%
• Previous Treatment 20%
• Risk Model 20%
• Sorafenib 40%
• Sunitinib 20%
• Targeted Therapy 100%
• Targeted Treatment 20%
• Temsirolimus 40%
• Therapy Treatment 20%
• Three-class 20%
• Treatment Options 60%
• Treatment Sequence 20%
• Tyrosine Kinase Inhibitor 20%
• Tyrosine Kinase Inhibitor Therapy 20%

Medicine and Dentistry

• Axitinib 33%
• Bevacizumab 16%
• Clear Cell 66%
• Clinical Trial 33%
• Cytokine Therapy 16%
• Diseases 16%
• Endothelial Cell Growth Factor 16%
• Everolimus 16%
• Hope 16%
• Kidney Metastasis 100%
• Malignant Neoplasm 16%
• Mammalian Target of Rapamycin Complex 1 16%
• Monoclonal Antibody 16%
• Pazopanib 16%
• Phosphotransferase Inhibitor 16%
• Sorafenib 33%
• Sunitinib 16%
• Targeted Therapy 100%
• Temsirolimus 33%
• Tyrosine-Kinase Inhibitor 50%
• Vasculotropin 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Axitinib 33%
• Bevacizumab 16%
• Clinical Trial 33%
• Cytokine 16%
• Diseases 16%
• Endothelial Cell Growth Factor 16%
• Everolimus 16%
• Kidney Metastasis 100%
• Malignant Neoplasm 16%
• Mammalian Target of Rapamycin Complex 1 16%
• Monoclonal Antibody 16%
• Pazopanib 16%
• Phosphotransferase Inhibitor 16%
• Protein Tyrosine Kinase Inhibitor 50%
• Sorafenib 33%
• Sunitinib 16%
• Temsirolimus 33%
• Vasculotropin 16%